Antibodies to reverse transcriptase in HIV infection and progression to AIDS
| Autor: | Joseph Kaminchik, Ami Schattner, Ziva Yavin, Zvi Bentwich, Ruth Milchan |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
CD4-Positive T-Lymphocytes
Male Immunology CD4-CD8 Ratio Human immunodeficiency virus (HIV) Enzyme-Linked Immunosorbent Assay HIV Infections HIV Antibodies medicine.disease_cause T-Lymphocytes Regulatory Virus Acquired immunodeficiency syndrome (AIDS) Immunopathology HIV Seropositivity medicine Humans Immunology and Allergy Patient group Acquired Immunodeficiency Syndrome biology RNA-Directed DNA Polymerase medicine.disease HIV Reverse Transcriptase Reverse transcriptase HIV-1 biology.protein Viral disease Antibody |
| Zdroj: | Immunology Letters. 33:207-210 |
| ISSN: | 0165-2478 |
| DOI: | 10.1016/0165-2478(92)90048-s |
| Popis: | Serum antibodies to the reverse transcriptase (ART) of human immunodeficiency virus 1 (HIV-1) were sequentially determined by ELISA in a group of 41 HIV-seropositive male homosexuals and 101 matched healthy controls, over 1.5-6 years (mean follow-up 3.25 years). Mean ART levels were significantly higher in the patient group as compared to the controls (195 +/- 75 vs. 75 +/- 45 absorbance (A) units; P less than 0.05). When analyzed in parallel with clinical evaluation and T-cell subset determinations, a "surge" in ART activity was associated with a more favourable course: eleven patients whose ART profile showed an increase greater than 100 A units (mean delta A 159.6 units) showed an attenuated decrease of CD4+ (T helper) lymphocytes with a mean time of 42.5 months to reach a CD4+ number of 400 cells/mm3. In contrast, 25 matched seropositive patients whose ART remained constant became CD4+ less than 400 cells/mm3 within a mean time of 10.8 months (P less than 0.05). These results as well as individual patients' data support a surge in serum ART as a favourable prognostic indicator, and may indicate a protective role for this antibody which should be followed up and possibly utilized in the treatment or in the design of a vaccine against HIV-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|